Fierce Pharma Asia—Takeda R&D chief's new strategy; AZ, Daiichi's ADC nod; Fosun's failed Henlius buy
Takeda's R&D chief explained the company's new investment priorities. AstraZeneca and Daiichi Sankyo's second antibody-drug conjugate has won its initial FDA approval in breast cancer. Fosun Pharma's attempt to privatize Henlius Biotech …